Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline

Executive Summary

The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.

You may also be interested in...



AstraZeneca Silent On Pfizer, Uses Growth And Pipeline To Speak For Its Prospects

AstraZeneca played it straight when reporting a strong second quarter, outlining a robust late stage pipeline, a growing list of early assets and collaborations, while avoiding “the elephant in the room” - predator Pfizer’s paused-pursuit of the U.K. pharma.

“Excellence In Execution” Is Key To AstraZeneca’s Bid To Be An Oncology Leader

Though AstraZeneca is in several ways playing catch up in the oncology space, a strategy built around speed, differentiation and carving out areas of leadership has the firm poised for transformation. Execs are particularly confident the company will become a dominant force as combinations become a larger part of cancer care, pulling from its immunotherapeutic and small molecule pipelines.

AstraZeneca Playing Leapfrog In Immunotherapy: How It Plans To Lead From Behind

AstraZeneca has not been at the front of the PD-1/L1 immune checkpoint inhibitor race, but execs explain how the company is making strategic choices in immuno-oncology to make it first to the finish line in unique areas.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS056141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel